This study conducted a systematic clinical observation of the clinical efficacy of UCB-MNCs in the treatment of hormone-resistant or hormone-dependent ulcerative colitis, in order to observe its clinical safety and efficacy.

This study adopts a randomized and controlled clinical research design. Patients are randomly divided into conventional treatment control group and UCB-MNCs treatment test group. The control group is given conventional treatment: prednisone combined azathioprine or adalimumab; the test group is given conventional treatment combined UCB-MNCs treatment, follow-up observations were carried out, in order to observe the clinical efficacy and safety of UCB-MNCs in the treatment of hormone resistance or hormone-dependent ulcerative colitis.

Inclusion Criteria:

• 1. Western medicine diagnosis is consistent with patients with refractory ulcerative colitis.
• 2. 18 Years to 65 Years，male or female.
• 3. Those who voluntarily participate in this clinical study and have signed an informed consent.

Exclusion Criteria:

• 1. Patients with non-refractory UC.
• 2. Those who are pregnant or breastfeeding, or have a childbirth plan in the near future.
• 3. People with severe allergies or allergies to known ingredients in basic treatments.
• 4. Patients with severe primary diseases such as severe cardiovascular and cerebrovascular diseases, liver and kidney, and hematopoietic system.
• 5. There are serious complications, such as local stenosis, intestinal obstruction, intestinal perforation, multiple intestinal polyps, toxic megacolon, rectal cancer, etc..
• 6. Patients with mental disorders and intellectual disabilities.
• 7. Patients who have participated in clinical studies of other drugs in the past 3 months.
• 8. Those who are seriously ill and need emergency treatment.
• 9. Patients who are still undergoing other treatment options for ulcerative colitis.
• 10. Researchers believe that it is not suitable for entry.